Literature DB >> 12940927

Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis.

C Högenauer1, H H Wenzl, T A Hinterleitner, W Petritsch.   

Abstract

BACKGROUND: Steroid refractory ulcerative colitis is most commonly treated with intravenous ciclosporin to avoid colectomy. In search for an alternative drug that can be administered orally we investigated oral tacrolimus (FK 506) for this indication.
METHODS: Nine patients with active, moderate/severe steroid refractory UC were treated with oral tacrolimus with a daily dose of 0.15 mg/kg body weight. After patients had responded azathioprine was added for long-term immunosuppression.
RESULTS: All patients responded within 1-2 weeks. After 12 weeks of tacrolimus therapy six patients (67%) were in complete remission, two patients (22%) had mild to moderate disease activity, and one patient (11%) underwent colectomy. After a mean follow up of 21 months six of the nine patients (67%) had their colon in situ. Two patients developed severe side-effects, one thrombopenia with intestinal bleeding, and one bicytopenia. Mild side-effects were common.
CONCLUSION: Oral tacrolimus may be an effective alternative to intravenous ciclosporin for the therapy of steroid-refractory ulcerative colitis. Patients receiving tacrolimus need to be watched carefully for side-effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12940927     DOI: 10.1046/j.1365-2036.2003.01662.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  19 in total

Review 1.  The role of tacrolimus in inflammatory bowel disease: a systematic review.

Authors:  Yago Gonzalez-Lama; Javier P Gisbert; Jose Mate
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

2.  A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content.

Authors:  Alan L Buchman; Mary F Paine; Anita Wallin; Shana S Ludington
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

3.  Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis.

Authors:  Ken Kawakami; Takuya Inoue; Mitsuyuki Murano; Ken Narabayashi; Sadaharu Nouda; Kumi Ishida; Yosuke Abe; Koji Nogami; Nobuyuki Hida; Hirokazu Yamagami; Kenji Watanabe; Eiji Umegaki; Shiro Nakamura; Tetsuo Arakawa; Kazuhide Higuchi
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

4.  Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis.

Authors:  Hu Zhang; Qin Ouyang; Zhong-Hui Wen; Claudio Fiocchi; Wei-Ping Liu; Dai-Yun Chen; Feng-Yuan Li
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

Review 5.  Current therapy of inflammatory bowel disease in children.

Authors:  Paul A Rufo; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 6.  The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease.

Authors:  Makoto Naganuma; Toshimitsu Fujii; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2010-12-04       Impact factor: 7.527

7.  The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease.

Authors:  Hiroyuki Tamaki; Hiroshi Nakase; Minoru Matsuura; Satoko Inoue; Sakae Mikami; Satoru Ueno; Norimitsu Uza; Hiroshi Kitamura; Katsuhiro Kasahara; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2008-10-29       Impact factor: 7.527

Review 8.  What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

Authors:  Ian C Lawrance
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

9.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.

Authors:  H Ogata; T Matsui; M Nakamura; M Iida; M Takazoe; Y Suzuki; T Hibi
Journal:  Gut       Date:  2006-02-16       Impact factor: 23.059

10.  Local immune regulation of mucosal inflammation by tacrolimus.

Authors:  Jolanda M van Dieren; Margaretha E H Lambers; Ernst J Kuipers; Janneke N Samsom; C Janneke van der Woude; Edward E S Nieuwenhuis
Journal:  Dig Dis Sci       Date:  2009-12-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.